版本:
中国

BRIEF-Arqule trial did not meet its primary endpoint of progression free survival

March 27 Arqule Inc

* Trial did not meet its primary endpoint of progression free survival (pfs).

* There were no new safety issues observed in trial

* Its partner, Kyowa Hakko Kirin, announced top-line results of JET-HCC phase 3 trial of Tivantinib in Japan Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐